Related Experiment Videos
Thorotrast-induced cholangiocarcinoma: case report
D Sahani1, S R Prasad, K K Tannabe
1Department of Radiology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.
Abdominal Imaging
|December 17, 2002
Summary
Thorotrast, a radioactive contrast agent, significantly increases cancer risk. This case highlights a cholangiocarcinoma developing 48 years after Thorotrast exposure, emphasizing its long-term dangers.
Area of Science:
- Radiology
- Oncology
- Medical Imaging
Background:
- Thorotrast, a formerly used radioactive contrast agent, emits high linear energy transfer radiation.
- This radiation is known to increase the risk of developing malignancies.
- Its use was discontinued in the 1950s due to safety concerns.
Observation:
- A patient developed peripheral cholangiocarcinoma.
- The patient had a history of Thorotrast exposure 48 years prior to diagnosis.
- The case involved detailed imaging analysis.
Findings:
- Computed tomography (CT) and magnetic resonance imaging (MRI) were used to characterize the tumor.
- The imaging features of peripheral cholangiocarcinoma in this context were documented.
- The long latency period between Thorotrast exposure and cancer development was noted.
Implications:
- This case underscores the prolonged oncogenic risk associated with Thorotrast exposure.
- It highlights the importance of considering past Thorotrast use in patients presenting with specific malignancies.
- Advanced imaging modalities are crucial for diagnosing and characterizing such rare cancers.